About Nobilis Therapeutics, Inc. Nobilis Therapeutics is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using portable controlled device administration of inert gases. The Company has filed multiple patents on the use of inert gases for treatment of a variety of psychiatric, neurodegenerative and other diseases and leverages the experience of its international team that has studied this technology in the treatment of over 2500 patients for conditions ranging from panic attacks to substance abuse. Company’s first clinical trial in 81 patients with Panic Disorder showed significant signals of efficacy. In 2016 the Company entered into an exclusive licensing agreement with Harvard University on the use of NBTX-001 in PTSD and had a patent issued the next year. Of its 14 independently filed patents 3 have been issued. In January of 2019 the Company had entered into collaboration with Linde AG to support its medical device and clinical development program.
Contact: Vlad Bogin, MD, FACP US Bancorp Tower, 111 S.W. Fifth Avenue, Suite 3150, Portland, OR, 97204 Tel: (971) 229-1679 Email: [email protected] Website: https://www.nobilistx.com Twitter: @nobilistx
PORTLAND, Ore., May 2, 2020 – Nobilis Therapeutics announced
today the issuance of a Notice of Allowance (European Patent Application No: 16815312.0) for a patent titled “Therapeutic immune modulation using noble gas compositions.”
“We have uncovered substantial signals of evidence that our drug possesses
strong anti-inflammatory and immunomodulatory effects,” said Vlad Bogin, CEO of Nobilis Therapeutics. “Given that there appears to be a strong correlation between CNS inflammation and psychiatric illness, we believe that the effects of NBTX-001 are at least in part modulated through its anti-inflammatory properties,” continued Dr. Bogin.